SPEXZ Stock Overview
A clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Spexis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.054 |
| 52 Week High | CHF 0.35 |
| 52 Week Low | CHF 0.031 |
| Beta | 0.19 |
| 11 Month Change | 0% |
| 3 Month Change | -1.10% |
| 1 Year Change | n/a |
| 33 Year Change | -97.11% |
| 5 Year Change | n/a |
| Change since IPO | -99.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| SPEXZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -5.2% | 0.8% |
| 1Y | n/a | -20.1% | 6.6% |
Return vs Industry: Insufficient data to determine how SPEXZ performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how SPEXZ performed against the UK Market.
Price Volatility
| SPEXZ volatility | |
|---|---|
| SPEXZ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SPEXZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine SPEXZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | Jeff Wager | spexisbio.com |
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs. Spexis AG is headquartered in Allschwil, Switzerland.
Spexis AG Fundamentals Summary
| SPEXZ fundamental statistics | |
|---|---|
| Market cap | CHF 2.03m |
| Earnings (TTM) | -CHF 19.62m |
| Revenue (TTM) | CHF 595.35k |
3.4x
P/S Ratio-0.1x
P/E RatioIs SPEXZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPEXZ income statement (TTM) | |
|---|---|
| Revenue | CHF 595.35k |
| Cost of Revenue | CHF 0 |
| Gross Profit | CHF 595.35k |
| Other Expenses | CHF 20.21m |
| Earnings | -CHF 19.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,295.35% |
| Debt/Equity Ratio | 222.4% |
How did SPEXZ perform over the long term?
See historical performance and comparison